Reply to direct‐acting antiviral drugs and hepatitis C virus: A therapeutic revolution?

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4269-4270

John Wiley & Sons Inc

Access to resources Recommend Favorite

P076: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct‐acting antiviral treatments

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 58-58

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will IL28B polymorphism remain relevant in the era of direct‐acting antiviral agents for hepatitis C virus?

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 373-381

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 7-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

The influence of immunosuppressants on direct‐acting antiviral therapy is dependent on the hepatitis C virus genotype

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 20, Iss. 1, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite